EGFR and non-small cell lung carcinoma: The clinical outcomes of KRASG12C-mutant NSCLC treated with KRASG12C inhibitors were worse than those of EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors [3, 4, 30].